CSO, CFO, and GC added as technology-enabled pharma company bolsters growing management team and SAB SAN FRANCISCO, Calif. — January 25, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer. Additional management team appointments include Jonathan Barr […]
Leading AI-pharma company among select few private companies to participate San Francisco, CA – January 5, 2022 – Atomwise, a technology-enabled pharmaceutical company leveraging the power of artificial intelligence (AI) to revolutionize small molecule drug discovery, today announced that it has been invited to present next week at the 40th Annual J.P. Morgan Healthcare Conference. […]
Experts include Mike Varney, Bruce Roth, John Hamer, Kemal Malik, and Andrew Lo SAN FRANCISCO, Calif., June 17, 2021 – Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on […]